Page 40 - Simon Hicks News Today : Breaking News, Live Updates & Top Stories | Vimarsana

      ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, today announces audited preliminary results for the year ended 31 December 2020.     · Full De Novo Submission made in September 2020 for US Food and Drug Administration (FDA) clearance of the Parsortix ® system for capturing and harvesting circulating tumour cells from metastatic breast cancer patients -  FDA Administrative Review complete and Substantive Review in progress -  FDA Additional Information Request (AIR) received and response planned for ...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...

ANGLE plc: Angle PLC- Ovarian Cancer Study Patient Enrolment Completed Headline results from the Study expected in Q4 2021 Study designed to support launch of an ovarian cancer test from ANGLE's clinical laboratories in the United States and the UK GUILDFORD, SURREY, UK / ACCESSWIRE / April 26, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that its 200 patient ovarian cancer clinical verification study ("the Study") has completed patient enrolment. The Study, undertaken by the University of Rochester Medical Center Wilmot Cancer Institu...

About ANGLE plc   www.angleplc.com   ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.   ANGLE's cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple type...

Investegate announcements from Barkby Group PLC, Cambridge Sleep Sciences signs new partners